Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.42 · Revenue $12.99B · 15 analysts
Est. EPS $1.64 · Revenue $13.54B · 14 analysts
Est. EPS $5.52 · Revenue $50.31B · 17 analysts
Est. EPS $1.28 · Revenue $12.79B · 8 analysts
$2.48 per share
$2.48 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $44.3B | +5.7% | +12.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $6.5B | -51.3% | -13.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +55.5% | +9.2% | +3.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +18.2% | +11.6% | -14.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +14.7% | -53.9% | -23.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $7.4B | +16.4% | +215.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +16.7% | +10.2% | +179.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 28.9% | -9.8% | -2.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.58x | -5.7% | -0.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $86.7B | +6.5% | -1.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 3.72 vs 5.15 | -27.8% | 0.53 vs 1.42 | -62.7% |
| Revenue Surprise | $44.3B vs $44.7B | -0.8% | $12.6B vs $13.0B | -3.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | MCCOY JOHN A. JR. | officer: VICE PRESIDENT AND CONTROLLER | Common shares without par value | D | 27 | $109.54 |
| Sep 1, 2026 | MCCOY JOHN A. JR. | officer: VICE PRESIDENT AND CONTROLLER | Common shares without par value | D | 52 | $110.36 |
| Sep 1, 2026 | Boudreau Philip P | officer: EVP AND CFO | Common shares without par value | D | 388 | $110.36 |
| Aug 25, 2026 | Ford Robert B | director, officer: CHAIRMAN AND CEO | Common shares without par value | A | 246,963 | $59.94 |
| Aug 25, 2026 | Ford Robert B | director, officer: CHAIRMAN AND CEO | Common shares without par value | D | 218,535 | $115.57 |
Operator: Good morning, and thank you for standing by. Welcome to Abbott's Second Quarter 26 Earnings Conference Call. During the question and answer session, you will be able to ask your question by pressing the star 1 keys on your touch tone phone. This call is being recorded by Abbott. With the exception of any participants' questions asked during the question and answer session, the entire call, including the question and answer session, is material copyrighted by Abbott It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Michael Comilla, Vice President, Investor Relations. Michael Comilla: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer and Philip Boudreau, Executive Vice President finance, and chief financial officer. Robert and Philip will provide opening remarks Following their comments, we will take your questions. Before we get started, some statements made today may be forward looking for purposes of the Private Securities Litigation Reform Act of 2000, including the expected financial results for 2026. Abbott cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10 k for the year ended 12/31/2025. Abbott undertakes no obligation to release publicly any revisions to forward looking statements as a result of subsequent events or developments except as required by law. On today's conference call, as in the past, non GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings news release regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the related GAAP financial measures on a forward looking basis for the non GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items, which could significantly impact Abbott's results in accordance with GAAP. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth. Our definition of comparable sales growth can be found on Page 2 of our press release issued earlier today. And a reconciliation table containing the data needed to calculate comparable sales for growth can be found on pages 16 and 17. With that, I will now turn the call over to Robert Ford. Robert Ford: Okay. Mike, good morning, everyone, and thank you for joining us. Today, we issued second quarter results that included sales …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Robert Ford | Executive Chairman & CEO | USD 4,428,548 | Male | 1974 | Active |
Elizabeth Cushman | Executive Vice President, General Counsel & Secretary | USD 2,546,024 | Female | 1970 | Active |
Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices | USD 2,386,584 | Female | 1970 | Active |
Philip Boudreau | Chief Financial Officer & Executive Vice President of Finance | USD 2,104,049 | Male | 1973 | Active |
Christopher J. Scoggins | Executive Vice President of Diabetes Care | USD 2,063,245 | Male | 1970 | Active |
Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products | USD 1,524,932 | Male | 1979 | Active |
Scott Michael Leinenweber | Senior Vice President of Licensing, Acquisitions & Ventures | — | Male | 1972 | Active |
Mary K. Moreland | Executive Vice President of Human Resources | — | Female | 1966 | Active |
Michael Comilla | Vice President of Investor Relations. | — | Male | — | Active |
Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer | — | Female | 1974 | Active |
Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer | — | — | — | Active |
Melissa Brotz | Senior Vice President of Global Marketing & External Affairs | — | Female | — | Active |
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.
Chelsea Counsel Co. decreased its holdings in shares of Abbott Laboratories (NYSE: ABT) by 23.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,311 shares of the healthcare product maker's stock after selling 5,000 shares during the period. Chelsea Counsel Co.'s holdings in
Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition products. Eli Lilly is experiencing rapid growth driven by its dominant presence in the cardiometabolic treatment market.
Abbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences. Johnson & Johnson maintains superior net margins and massive scale within its pharmaceutical and medical technology divisions.
Bank of America Corp DE cut its position in Abbott Laboratories (NYSE: ABT) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,279,608 shares of the healthcare product maker's stock after selling 551,015 shares during the quarter. Bank
